Who are MED ON plus's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): histamine dihydrochloride and IL-2, Entecavir + Pegylated interferon α-2b, β-1,3/1,6-D-glucan, Glatiramer acetate (GA), Thymosin Alpha 1, Tailored Group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/med-on-plus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

MED ON plus — Competitive Intelligence Brief

MED ON plus (MED ON plus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: immunomodulator. Area: Neurology.

marketed immunomodulator Neurology Small molecule Live · refreshed every 30 min

Target snapshot

MED ON plus (MED ON plus) — IRCCS Istituto delle Scienze Neurologiche di Bologna. MED ON plus is a medication used to treat multiple sclerosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MED ON plus TARGET	MED ON plus	IRCCS Istituto delle Scienze Neurologiche di Bologna	marketed	immunomodulator
histamine dihydrochloride and IL-2	histamine dihydrochloride and IL-2	Cytovia, Inc.	marketed	Immunomodulator combination	Histamine receptors (H1, H2, H3, H4) and IL-2 receptor
Entecavir + Pegylated interferon α-2b	Entecavir + Pegylated interferon α-2b	Qing-Lei Zeng	marketed	Antiviral combination (nucleoside reverse transcriptase inhibitor + immunomodulator)	HBV reverse transcriptase; interferon-α receptor
β-1,3/1,6-D-glucan	β-1,3/1,6-D-glucan	Al-Azhar University	marketed	Immunomodulator; biological response modifier	Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3)
Glatiramer acetate (GA)	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
Thymosin Alpha 1	Thymosin Alpha 1	Xuanwu Hospital, Beijing	marketed	Immunomodulator	T-cell maturation pathway / thymic differentiation
Tailored Group	Tailored Group	Beijing Children's Hospital	marketed	Immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (immunomodulator class)

IRCCS Istituto delle Scienze Neurologiche di Bologna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MED ON plus — Competitive Intelligence Brief. https://druglandscape.com/ci/med-on-plus. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab